Cited by 109Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsReproductive Biology and Fertility

Metformin in polycystic ovary syndrome

Diamanti‐Kandarakis, Evanthia, Economou, Frangiskos, Palimeri, Sotiria, Christakou, Charikleia·2010·Annals of the New York Academy of Sciences

Abstract

Polycystic ovary syndrome (PCOS) affects 6.6–6.8% of women in reproductive age. Insulin resistance and hyperinsulinemia play a critical role in the pathogenesis of PCOS and are associated with a high risk for type 2 diabetes mellitus and cardiometabolic abnormalities. Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance. The tissue‐specific actions of metformin as well as the molecular mechanisms involved in the liver, the muscle, the endothelium, and the ovary are elucidated in this review. The use of metformin in pregnant women with PCOS is another of its positive features. Overall, available data supports the therapeutic usefulness of metformin on cardiometabolic risk and reproduction assistance in PCOS women.

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2010.05679.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Diamanti‐Kandarakis, E., Economou, F., Palimeri, S., & Christakou, C.
Affiliations
National and Kapodistrian University of Athens (GR)
Corresponding author
Diamanti‐Kandarakis, Evanthia
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2010-09
Volume
1205
Issue
1
Pages
192-198
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2127037921
Cited by
109
References
4
Citations by year
2026: 2 · 2025: 8 · 2024: 9 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 9 · 2019: 6 · 2018: 4 · 2017: 7 · 2016: 4 · 2015: 6 · 2014: 5 · 2013: 7 · 2012: 12
FWCI
12.57
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of the New York Academy of Sciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
Keywords
metformin, polycystic ovary syndrome, insulin resistance, hyperinsulinemia, type 2 diabetes, cardiometabolic risk, reproductive outcomes, ovary
MeSH terms
Cardiovascular Diseases, Female, Humans, Hypoglycemic Agents, Infertility, Female, Metabolic Diseases, Metformin, Polycystic Ovary Syndrome, Pregnancy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review